Upper Tract Urothelial Carcinoma (UTUC) may be found in the bladder, kidney, ureter and urethra but it is mostly found in the bladder.

The main types of immunotherapy to fight urothelial cancers are called **Immune Checkpoint Inhibitors**.

Immune checkpoint inhibitors are antibodies given intravenously to block the “checkpoints” that cancer cells use to avoid being attacked by the immune system.

**Immunotherapy drugs to treat advanced UC include:**
- atezolizumab
- durvalumab
- avelumab
- nivolumab
- pembrolizumab

**WHY USE IMMUNOTHERAPY?**

Immunotherapy helps the immune system destroy cancer cells.

**RISKS AND BENEFITS**

Of intravenous immunotherapy for urothelial cancer patients.

Common **RISKS** of urothelial cancer include:
- fluid loss
- vomiting
- unusual stools
- diarrhea
- yellow skin/eyes
- fever
- chest pain
- wheezing
- coughing

While patients can benefit, there is a risk that healthy cells may be targeted. Autoimmune problems are usually manageable but, in rare cases, can be serious.

**EFFECTIVE** in treating urothelial cancer

**For more information about kidney cancer and immunotherapy, visit the Urology Care Foundation’s website:**

For more information about kidney cancer and immunotherapy, visit the Urology Care Foundation’s website: UrologyHealth.org

Supported by an independent educational grant from Merck & Co., Inc.